8-Hydroxy-2-(di-n-propylamino) Tetralin is Devoid of Activity at the 5-hydroxytryptamine Autoreceptor in Rat Brain. Implications for the Proposed Link Between the Autoreceptor and the [3H] 5-HT Recognition Site
Overview
Authors
Affiliations
Experiments have been carried out to provide direct evidence for the proposed presynaptic 5-HT autoreceptor agonist activity of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) a compound with selectivity for the 5-HT1A subtype of the 5-HT1 binding site. Rat brain frontal cortex slices were preincubated with [3H] 5-hydroxytryptamine and continuously stimulated with Krebs solution containing paroxetine and elevated K+ ions (25 mmol/l). The elevated efflux of tritium caused by exposure to K+ Krebs was inhibited in a dose related manner by 5-hydroxytryptamine and this inhibition was attenuated in the presence of quipazine and methiothepin. In slices of the rat frontal cortex, 8-OH-DPAT was without agonist or antagonist activity at the 5-HT autoreceptor at concentrations up to 1 mmol/l. Higher concentrations caused an increase in basal efflux of tritium. 8-OH-DPAT (1 mumol/l) was also without inhibitory activity in the piriform cortex, striatum and the hippocampus. These experiments have therefore failed to provide direct evidence for agonist activity of 8-OH-DPAT at the 5-HT autoreceptor and alternative explanations must be sought for its biochemical and behavioural effects in vivo. Moreover, the fact that 8-OH-DPAT is inactive at the autoreceptor at concentrations selective for the 5-HT1A recognition site suggests that this subtype of the 5-HT1 binding site may not correspond to the 5-HT autoreceptor.
Sayer T, Hannon S, Redfern P, Martin K Br J Pharmacol. 1999; 126(8):1777-84.
PMID: 10372820 PMC: 1565973. DOI: 10.1038/sj.bjp.0702535.
Cheetham S, Heal D Br J Pharmacol. 1993; 110(4):1621-9.
PMID: 8306109 PMC: 2175846. DOI: 10.1111/j.1476-5381.1993.tb14010.x.
Richards M Naunyn Schmiedebergs Arch Pharmacol. 1985; 329(4):359-66.
PMID: 4033805 DOI: 10.1007/BF00496368.
Charlton K, Bond R, Clarke D Naunyn Schmiedebergs Arch Pharmacol. 1986; 332(1):8-15.
PMID: 3951568 DOI: 10.1007/BF00633190.
Maura G, Roccatagliata E, Raiteri M Naunyn Schmiedebergs Arch Pharmacol. 1986; 334(4):323-6.
PMID: 3821924 DOI: 10.1007/BF00569364.